Crizotinib inhibits migration and expression of ID1 in MET-positive lung cancer cells: implications for MET targeting in oncology | Future Oncology
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine
Crizotinib inhibits c-MET activation and shows in-vitro efficacy in CRC... | Download Scientific Diagram
Crizotinib hydrochloride | c-Met 阻害剤
Safety and Tolerability of c-MET Inhibitors in Cancer | SpringerLink
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - Cancer Treatment Reviews
Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers - Lung Cancer
PLOS ONE: Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors
cに応じられた阻害 | c-Met Inhibition
Crizotinib in Patients With MET-Amplified NSCLC - Journal of Thoracic Oncology
Effects of crizotinib on ALK/MET phosphorylation, AKT and ERK... | Download Scientific Diagram
Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non–small-cell Lung Cancer - Clinical Lung Cancer
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? - Journal of Thoracic Oncology
PLOS ONE: Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation - Lung Cancer
Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification - Annals of Oncology
Crizotinib, a MET inhibitor, prevents peritoneal dissemination in pancreatic cancer
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. | Semantic Scholar
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine
MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations - Journal of Thoracic Oncology
Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial - Annals of Oncology
Cyclosporine A sensitizes lung cancer cells to crizotinib through inhibition of the Ca2+/calcineurin/Erk pathway - eBioMedicine
